Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

Autor: Minarik, Jiri1 (AUTHOR) abretina@email.cz, Pika, Tomas1 (AUTHOR), Radocha, Jakub2 (AUTHOR), Jungova, Alexandra3 (AUTHOR), Straub, Jan4 (AUTHOR), Jelinek, Tomas5 (AUTHOR), Pour, Ludek6 (AUTHOR), Pavlicek, Petr7 (AUTHOR), Mistrik, Martin8 (AUTHOR), Brozova, Lucie9 (AUTHOR), Krhovska, Petra1 (AUTHOR), Machalkova, Katerina2 (AUTHOR), Jindra, Pavel3 (AUTHOR), Spicka, Ivan4 (AUTHOR), Plonkova, Hana5 (AUTHOR), Stork, Martin6 (AUTHOR), Bacovsky, Jaroslav1 (AUTHOR), Capkova, Lenka9 (AUTHOR), Sykora, Michal10 (AUTHOR), Kessler, Petr11 (AUTHOR)
Zdroj: BMC Cancer. 1/15/2021, Vol. 21 Issue 1, p1-13. 13p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje